OR-1855
OR-1855, an active metabolite of Levosimendan , has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD (P) H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation[1][2][3].
Product Specifications
CAS Number
101328-85-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Drug Metabolite; ERK; p38 MAPK; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/or-1855.html
Concentration
10mM
Purity
99.78
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C[C@@H](C)C(C2=CC=C(N)C=C2)=NN1
Molecular Formula
C11H13N3O
Molecular Weight
203.25
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Human Endoplasmic Reticulum To Nucleus Signalling 1 (ERN1) ELISA Kit
Human Endoplasmic Reticulum To Nucleus Signalling 1 (ERN1) ELISA Kit
Cyclin G (CCNG1) (NM_199246) Human Over-expression Lysate
